DSIP
Endogenous neuropeptide (Delta Sleep-Inducing Peptide, nonapeptide)
Delta sleep-inducing peptide, a nonapeptide studied in sleep and neurological research.
Also referenced as: Delta Sleep-Inducing Peptide
Overview
Delta Sleep-Inducing Peptide (DSIP) was originally isolated in the 1970s from the cerebral venous blood of rabbits during induced sleep by researchers in Switzerland. It is a naturally occurring neuropeptide.
At a glance
What DSIP does
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the cerebral venous blood of rabbits whose sleep had been induced by electrical stimulation of the thalamus. What it does in research is, as the name implies, promote delta-wave (slow-wave) sleep: infused into the brain of animals it increases spindle and delta EEG activity and reduces locomotor activity. Beyond sleep, it has been linked to a surprisingly broad range of regulatory effects.
Its mechanism remains genuinely unresolved despite decades of study. DSIP does not have a single well-defined receptor identified as its target; instead it is reported to influence multiple neurotransmitter and hormone systems, modulating serotonin, glutamate, dopamine, and melatonin, and affecting circadian and hormonal (e.g., corticosteroid, LH) rhythms. This makes it look more like a broad neuromodulator than a dedicated sleep switch, and researchers explicitly note that the exact neurochemical pathways underlying its sleep effect are still unknown.
The evidence is old, heterogeneous, and often inconsistent. Effects have been reported across rabbits, rats, mice, and humans, and it has also been studied for stress resilience, pain, thermoregulation, and drug-withdrawal modulation. However, findings have been difficult to replicate reliably, some studies show weak or absent effects, and there is no modern large-scale controlled clinical program, so its practical sleep utility in humans remains poorly established.
Effects reported in research
- Increased delta-wave (slow-wave) and spindle EEG activity when infused into animal brain (animal).
- Reduced locomotor/motor activity accompanying its sleep-promoting effect (animal).
- Improved sleep measures in some insomnia models, including fusion-peptide and PCPA-induced insomnia studies (animal).
- Modulation of serotonin, glutamate, dopamine, and melatonin signaling (preclinical).
- Influence on circadian rhythms and hormonal secretion (e.g., corticosteroids, LH) (preclinical).
- Reported effects on stress resilience, pain, and thermoregulation (animal, heterogeneous).
- Reported modulation of drug tolerance and withdrawal in pharmacological studies (animal).
- No single defined receptor identified and no robust large-scale human sleep trials; mechanism remains uncertain.
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
DSIP is a neuropeptide historically associated with the promotion of delta-wave (slow-wave) sleep, though its exact receptor and mechanism of action remain poorly defined. Research has explored roles in stress modulation, neuroendocrine regulation, and antioxidant effects. Findings across studies have been inconsistent, and its physiological function is still not fully understood.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which DSIP appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- Named for its historical association with delta-wave sleep
- A naturally occurring nonapeptide first isolated in the 1970s
- Mechanism and receptor remain poorly characterized
- Research findings on its sleep and stress effects have been inconsistent
- Research-only; not an approved therapeutic
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. DSIP is a research compound.
Research references commonly cite roughly 100-300 mcg subcutaneously given before a target sleep period, with some human studies using weight-scaled intravenous doses. These are reference figures for research context only, not human dosing guidance.
- Common research reference: ~100-300 mcg subcutaneous
- Human sleep studies: ~25 nmol/kg intravenous
Serum half-life reported around ~7 minutes with limited in vitro stability; effects may involve carrier-protein or precursor forms
How it compares
DSIP is a naturally occurring sleep-associated neuropeptide with an undefined mechanism, distinguishing it from the cognition-focused synthetic peptides in this class.
Commonly studied alongside
Compounds frequently researched together with DSIP in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Compare and calculate
Side-by-side pages for the pairings the literature already documents for DSIP, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.
DSIP reconstitution calculator → Concentration, volume per measured amount and syringe units for a stated vial mass and diluent volume. A unit-conversion reference, not a dosing recommendation.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
DSIP sits in the Cognitive & Nootropic area of the PeptiDex library.
- Entry type: Research compound reference
- Cognitive & Nootropic category hub →
- Browse the full library →
- Glossary of terms →
Where researchers source DSIP
For researchers studying DSIP, third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US.
View research-supplier listing →
Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.
Frequently asked questions
What is DSIP (delta sleep-inducing peptide)?
DSIP is a nine-amino-acid neuropeptide first isolated in the 1970s and named for its association with delta-wave sleep in early animal experiments. It is studied for possible roles in sleep regulation, stress response, and neuroendocrine modulation, though its precise mechanism remains incompletely defined.
What is DSIP studied for beyond sleep?
In addition to sleep research, DSIP has been examined in models involving stress, pain, thermoregulation, and neuroendocrine function, reflecting a broad and not fully explained profile. Reviews describe it as a multifunctional peptide, which is part of why its mechanism is still debated.
What does DSIP's short half-life imply for research design?
DSIP is reported to have a serum half-life on the order of only several minutes and limited in vitro stability. This short exposure, combined with the observation that effects may involve carrier-protein complexes or precursor forms, is an important consideration when timing sleep-related endpoints in studies.
How is DSIP administered in research?
In research protocols DSIP is typically given by subcutaneous injection, and some human sleep studies used intravenous dosing scaled to body weight. It is supplied as a lyophilized peptide requiring reconstitution before use.
Is DSIP an approved drug?
No. DSIP is not an approved pharmaceutical and is handled as a research peptide. Despite decades of study, it has not been developed into an approved sleep medication.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.
References
Primary literature indexed in PubMed for DSIP. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle
- The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep
- Delta-sleep-inducing peptide (DSIP): a review
Each reference was checked against its PubMed record on 2026-07-28: the PMID resolves and the title, journal and year match. Where no indexed literature exists for a compound, PeptiDex says so rather than substituting a citation about a different molecule. See the editorial policy.